TantucciC, PaolettiF, BruniB, DottoriniML, PecciniF, BoanelliA, BelfioriR, PasqualucciV: Acute respiratory effects of sublingual buprenorphine: Comparison with intramuscular morphine. Int J Clin Pharmacol Ther Toxicol., 1992; 30:202–207.
3.
LikarR: Transdermal buprenorphine in the management of persistent pain: Safety aspects. Ther Clin Risk Manag., 2006; 2:115–125.
4.
WestermeyerJ, McCance-KatcEF: Course and treatment of buprenorphine/naloxone withdrawal: An analysis of case reports. Am J Addict., 2012; 21:401–403.
5.
TompkinsDA, SmithMT, MintzerMZ, CampbellCM, StrainEC: A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine. J Pharmacol Exp Ther., 2014; 348:217–226.
WiffenPJ, WeeB, MooreRA: Oral morphine for cancer pain. Cochrane Database Syst Rev., 2013; 7:CD003868.
8.
PayneR, MathiasSD, PastaDJ, WankeLA, WilliamsR, MahmoudR: Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol., 1998; 16:1588–1593.
9.
BrooksDJ, GambleW, AhmedzaiS: A regional survey of opioid use by patients receiving specialist palliative care. Palliat Med., 1995; 9:229–238.
